Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Provention Bio Inc (PRVB) Ordinary Shares

Sell:$11.57 Buy:$13.00 Change: $0.39 (3.39%)
NASDAQ:0.74%
Market closed |  Prices as at close on 19 July 2019 | Switch to live prices |
Sell:$11.57
Buy:$13.00
Change: $0.39 (3.39%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 19 July 2019 | Switch to live prices |
Sell:$11.57
Buy:$13.00
Change: $0.39 (3.39%)
Market closed |  Prices as at close on 19 July 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.

Contact details

Address:
PO Box 666
OLDWICK
08858-0666
United States
Telephone:
+1 (908) 4289136
Website:
https://www.proventionbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PRVB
ISIN:
US74374N1028
Market cap:
$430.03 million
Shares in issue:
37.36 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ashleigh Palmer
    President, Chief Executive Officer, Director
  • Andrew Drechsler
    Chief Financial Officer
  • Eleanor Ramos
    Chief Operating Officer, Chief Medical Officer
  • Francisco Leon
    Chief Scientific Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.